Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • Epidemiology of HIV-related CVD in developing countries is largely unknown, although long-term data in the ART era are accumulating[Mutimura 2008a; Mutimura 2008b; Syed 2013; Almodovar 2010]
  • Prevention and management of CVD in resource-limited settings is hindered by lack of laboratory infrastructure and specialty management
  • Risk-factor reduction can be challenging because of the stresses of extreme poverty in managing lifestyle changes

Action required

Keywords: Cardiovascular Disease, Resource-Limited Settings, Treatment Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.